Recently Viewed
empty-cart

There are no Recent Items

Close
Login/Register

Close
Single User License Price USD 125
Single User License Price INR 8625
Corporate User License Price USD 375
Corporate User License Price INR 25875
Site License Price USD 250
Site License Price INR 17250
Request a Quote

Report Title

Supernus Pharmaceuticals Inc (SUPN)-Financial and Strategic SWOT Analysis Review

Quote Request for License Type
License Type Price  
Single User License USD 125
Site License USD 250
Enterprise Wide License USD 375
"Thanks for submitting the form. Our marketing team will connect back to you for the budget constraint."
Close
REQUEST A CUSTOMIZED RESEARCH

Report Title

Supernus Pharmaceuticals Inc (SUPN)-Financial and Strategic SWOT Analysis Review


Quote Request for License Type
License Type Price  
Single User License USD 125
"Thanks for letting us know your requirement. Our research team will connect back to you for the bespoke requirement."
Close
REQUEST FOR SAMPLE REPORT

Report Title

Supernus Pharmaceuticals Inc (SUPN)-Financial and Strategic SWOT Analysis Review

"Thanks for submitting the form. The concerned team will send the sample report in the next 12 hours."
"Thank you for downloading the sample report."
Close

Supernus Pharmaceuticals Inc (SUPN)-Financial and Strategic SWOT Analysis Review



Executive Summary

Supernus Pharmaceuticals Inc (SUPN)-Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company's businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

Business description-A detailed description of the company's operations and business divisions.

Corporate strategy-Analyst's summarization of the company's business strategy.

SWOT Analysis-A detailed analysis of the company's strengths, weakness, opportunities and threats.

Company history-Progression of key events associated with the company.

Major products and services-A list of major products, services and brands of the company.

Key competitors-A list of key competitors to the company.

Key employees-A list of the key executives of the company.

Executive biographies-A brief summary of the executives' employment history.

Key operational heads-A list of personnel heading key departments/functions.

Important locations and subsidiaries-A list and contact details of key locations and subsidiaries of the company.

Key manufacturing facilities-A list of key manufacturing facilities of the company.

Detailed financial ratios for the past five years-The latest financial ratios derived from the annual financial statements published by the company with 5 years history.

Interim ratios for the last five interim periods-The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Supernus Pharmaceuticals Inc (Supernus) is a specialty pharmaceutical company which develops and commercializes products for the treatment of central nervous system (CNS) diseases. The company's neurology portfolio consists of Oxtellar XR (oxcarbazepine), an adjunct therapy for the treatment of partial seizures; and Trokendi XR (topiramate), an initial monotherapy against partial onset or primary generalized tonic-clonic seizures and an adjunct therapy for the treatment of primary generalized tonic-clonic seizures associated with Lennox-Gastaut syndrome. Its technology platforms include Microtrol (multiparticulate delivery platform), Solutrol (matrix delivery platform) and EnSoTrol (osmotic delivery system). The company operates through its subsidiary Supernus Europe Ltd. Supernus is headquartered in Rockville, Maryland, the US.

Supernus Pharmaceuticals Inc Key Recent Developments

Feb 28,2017: Supernus Announces Record Fourth Quarter and Full Year 2016 Financial Results

Nov 14,2016: Supernus Provides Business Update

Aug 12,2016: Supernus Announces Resignation of Dr. James Barrett from Board of Directors; Charles W. Newhall, III Elected Chairman

Aug 02,2016: Supernus Announced Second Quarter 2016 Financial Results

Aug 02,2016: Supernus Announces Second Quarter 2016 Financial Results

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

The profile analyzes the company's business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors' business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

The company's core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies' strategic, financial and operational performance.

Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Section 1-About the Company 6

Supernus Pharmaceuticals Inc-Key Facts 6

Supernus Pharmaceuticals Inc-Key Employees 7

Supernus Pharmaceuticals Inc-Key Employee Biographies 8

Supernus Pharmaceuticals Inc-Major Products and Services 9

Supernus Pharmaceuticals Inc-Pharmaceutical Pipeline Products Data 10

Supernus Pharmaceuticals Inc, Pipeline Products by Therapy Area 10

Supernus Pharmaceuticals Inc, Pipeline Products by Development Phase 10

Supernus Pharmaceuticals Inc-History 12

Supernus Pharmaceuticals Inc-Company Statement 14

Supernus Pharmaceuticals Inc-Locations And Subsidiaries 15

Head Office 15

Other Locations & Subsidiaries 15

Section 2-Company Analysis 16

Supernus Pharmaceuticals Inc-Business Description 16

Supernus Pharmaceuticals Inc-Corporate Strategy 17

Supernus Pharmaceuticals Inc-SWOT Analysis 18

SWOT Analysis-Overview 18

Supernus Pharmaceuticals Inc-Strengths 18

Supernus Pharmaceuticals Inc-Weaknesses 19

Supernus Pharmaceuticals Inc-Opportunities 20

Supernus Pharmaceuticals Inc-Threats 21

Supernus Pharmaceuticals Inc-Key Competitors 22

Section 3-Company Financial Ratios 23

Financial Ratios-Capital Market Ratios 23

Financial Ratios-Annual Ratios 24

Performance Chart 26

Financial Performance 26

Financial Ratios-Interim Ratios 27

Financial Ratios-Ratio Charts 28

Section 4-Company's Lifesciences Financial Deals and Alliances 29

Supernus Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 29

Supernus Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Type, 2011 to YTD 2017 30

Supernus Pharmaceuticals Inc, Recent Deals Summary 31

Section 5-Company's Recent Developments 32

Feb 28, 2017: Supernus Announces Record Fourth Quarter and Full Year 2016 Financial Results 32

Nov 14, 2016: Supernus Provides Business Update 34

Aug 12, 2016: Supernus Announces Resignation of Dr. James Barrett from Board of Directors; Charles W. Newhall, III Elected Chairman 36

Aug 02, 2016: Supernus Announced Second Quarter 2016 Financial Results 37

Aug 02, 2016: Supernus Announces Second Quarter 2016 Financial Results 39

May 03, 2016: Supernus Announces First Quarter 2016 Financial Results 41

Apr 01, 2016: Supernus Pharmaceuticals Selects DSG for EDC and IWRS in Phase 3 Clinical Studies on Impulsive Aggression in Pediatric Patients Treated for Attention Deficit/Hyperactivity Disorder 43

Mar 02, 2016: Supernus Announces Record Fourth Quarter and Full Year 2015 Financial Results 44

Section 6-Appendix 46

Methodology 46

Ratio Definitions 46

About GlobalData 50

Contact Us 50

Disclaimer 50

To know more information on Purchase by Section, please send a mail to sales@kenresearch.com

List of Figures

Supernus Pharmaceuticals Inc, Pipeline Products by Therapy Area 10

Supernus Pharmaceuticals Inc, Pipeline Products by Development Phase 10

Supernus Pharmaceuticals Inc, Performance Chart (2012-2016) 26

Supernus Pharmaceuticals Inc, Ratio Charts 28

Supernus Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 29

Supernus Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 30

List of Tables

Supernus Pharmaceuticals Inc, Key Facts 6

Supernus Pharmaceuticals Inc, Key Employees 7

Supernus Pharmaceuticals Inc, Key Employee Biographies 8

Supernus Pharmaceuticals Inc, Major Products and Services 9

Supernus Pharmaceuticals Inc, Number of Pipeline Products by Development Stage 11

Supernus Pharmaceuticals Inc, History 12

Supernus Pharmaceuticals Inc, Subsidiaries 15

Supernus Pharmaceuticals Inc, Key Competitors 22

Supernus Pharmaceuticals Inc, Ratios based on current share price 23

Supernus Pharmaceuticals Inc 24

Supernus Pharmaceuticals Inc (Cont...1) 25

Supernus Pharmaceuticals Inc, Interim Ratios 27

Supernus Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 29

Supernus Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Type, 2011 to YTD 2017 30

Supernus Pharmaceuticals Inc, Recent Deals Summary 31

Currency Codes 46

Capital Market Ratios 46

Equity Ratios 47

Profitability Ratios 47

Cost Ratios 48

Liquidity Ratios 48

Leverage Ratios 49

Efficiency Ratios 49

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Sunovion Pharmaceuticals Inc Shire Plc Neurovance Inc Neos Therapeutics Inc Desitin Arzneimittel GmbH Alcobra Ltd

Supernus Pharmaceuticals Inc, SWOT analysis, SWOT, Strengths, Weaknesses, Opportunities, Threats, Corporate Strategy, Key Ratios, Share Data, Performance, Financial Performance, Overview, Business Description, Major Product, Brands, History,Key Employees, Key Operational Heads, Strategy, Key Competitors, Company Statement, Capital Market Ratios, Financial Ratios, Annual Ratios, Interim Ratios, Ratio Charts


Related Products in vertical
red-whiteline

RECENT VIEWED REPORTS



Sign up for newsletter

Close
Apply For Job

  • Applicant Name
  • Job Function
  • Total Experience
  • Skills
  • Email ID
  • Notice Period
  • Current CTC & Expected CTC
  • Phone Number
  • Validation
  • captcha  info-icon

    If validation code does not match, please refresh the page.

  • "Your resume has been successfully received. HR will connect you within 14 days in case your resume gets shortlisted."
Close
Download Company Brochure

  • Name
  • Email
  • Company Name
  • Select Country*
  • Phone Number
  • Validation
  •   info-icon

    If validation code does not match, please refresh the page.

Close
Engage With Us

  • Name
  • Designation
  • Email
  • Phone No.
  • Company Name
  • Company URL
  • Select Country*
  • Requirements/ Comments
  • Validation
  • captcha  info-icon

    If validation code does not match, please refresh the page.

  • "Thanks for submitting the form. The concerned team will respond to your query in the next 8-12 hours"
Close

Compare

Expand

person